ArticleThe Journal of clinical investigation2018

Targeting the aryl hydrocarbon receptor/polyamine biosynthesis axis of evil for cancer therapy.

Robert A CaseroPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.